Leo Fu

Co-Founder, CTO

GluBio Pharmaceutical

Short Biography

Liqiang (Leo) Fu has an extensive work experience in the biotechnology and pharmaceutical industries. Leo is currently working as the Co-Founder and Chief Technology Officer at GluBio Pharmaceutical, Co., Ltd., a position he has held since March 2021. From 2016 to 2021, Leo worked at Johnson & Johnson (Shanghai) Research & Development Center, where he held the position of Principal Scientist and Chemistry Head of Janssen (China) Protein Degradation Drug Discovery. Leo's career began at AbbVie in January 2014, where he worked as a group leader and Senior Scientist of Medicinal Chemistry. He has a track record of inventing or co-inventing several drug candidates that have advanced to clinical trials. Leo has authored or co-authored >20 publications and is an inventor on >20 patents and patent applications. Leo Fu holds a Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences and had his postdoctoral training with Prof. Blake R. Peterson at University of Kansas.

Presentation Topic: From Serendipity to AI-Driven Design: Accelerating the Discovery of Molecular Glue Degraders

• Introduction: The Discovery of Molecular Glues

• Breakthroughs in IMiD-Based Molecular Glues

• Evolution from Rational Design to AI-Powered Discovery

• AI-Driven Approaches in Molecular Glue Design

• GluBio’s Integrated Degrader Discovery GDD® Platform

• Conclusion and Future Directions